BioMarin Pharmaceuticals
BMRN
560 hedge funds and large institutions have $15.2B invested in BioMarin Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 88 funds opening new positions, 196 increasing their positions, 195 reducing their positions, and 80 closing their positions.
10% more first-time investments, than exits
New positions opened: 88 | Existing positions closed: 80
1% more repeat investments, than reductions
Existing positions increased: 196 | Existing positions reduced: 195
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
0% less funds holding
Funds holding: 561 → 560 (-1)
8% less call options, than puts
Call options by funds: $153M | Put options by funds: $166M
1.68% less ownership
Funds ownership: 99.02% → 97.34% (-1.7%)
7% less capital invested
Capital invested by funds: $16.3B → $15.2B (-$1.1B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$688M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$264M |
| 3 |
State Street
Boston,
Massachusetts
|
+$228M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$73M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$70.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$389M |
| 2 |
Barclays
London,
United Kingdom
|
-$344M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$147M |
| 4 |
Nomura Holdings
Tokyo,
Japan
|
-$124M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$118M |
BMRN Hedge Fund Activity: Q2 2024 in Review
560 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q2 2024, worth a combined $15.2B — down 6.8% from $16.3B a quarter earlier.
Buyers outnumbered sellers: 88 funds opened new BMRN positions and 80 closed out — a net gain of 8 holders — while 196 added to existing stakes and 195 trimmed.
The largest buyer was BlackRock, adding an estimated $688M. The largest seller was UBS Group, cutting an estimated $389M.
- 560 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q2 2024, down from 561 in Q1 2024.
- Funds reported $15.2B of BioMarin Pharmaceuticals stock for Q2 2024, down 6.8% quarter-over-quarter.
- 88 funds opened new BioMarin Pharmaceuticals positions in Q2 2024 and 80 closed out, a net change of +8 holders.
- The largest BioMarin Pharmaceuticals buyer in Q2 2024 was BlackRock, an estimated $688M added.
- The largest BioMarin Pharmaceuticals seller in Q2 2024 was UBS Group, an estimated $389M sold.
Based on aggregated 13F filings for Q2 2024.